Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996.

Literature DB >> 8869798

The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996.

S O'Reilly¹, E K Rowinsky.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 1996 PMID： 8869798 DOI： 10.1016/1040-8428(96)00211-9

Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN： 1040-8428 Impact factor: 6.312

Keyword Cloud
Cited

× No keyword cloud information.

16 in total

1. In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood.

Authors: O Combes; J Barré; J C Duché; L Vernillet; Y Archimbaud; M P Marietta; J P Tillement; S Urien
Journal: Invest New Drugs Date: 2000-02 Impact factor: 3.850

2. A self-contained enzyme activating prodrug cytotherapy for preclinical melanoma.

Authors: Gwi-Moon Seo; Raja Shekar Rachakatla; Sivasai Balivada; Marla Pyle; Tej B Shrestha; Matthew T Basel; Carl Myers; Hongwang Wang; Masaaki Tamura; Stefan H Bossmann; Deryl L Troyer
Journal: Mol Biol Rep Date: 2011-05-13 Impact factor: 2.316

3. A cell-delivered and cell-activated SN38-dextran prodrug increases survival in a murine disseminated pancreatic cancer model.

Authors: Matthew T Basel; Sivasai Balivada; Tej B Shrestha; Gwi-Moon Seo; Marla M Pyle; Masaaki Tamura; Stefan H Bossmann; Deryl L Troyer
Journal: Small Date: 2012-01-11 Impact factor: 13.281

4. Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine.

Authors: Laura W Goff; Al B Benson; Patricia M LoRusso; Antoinette R Tan; Jordan D Berlin; Louis J Denis; Rebecca J Benner; Donghua Yin; Mace L Rothenberg
Journal: Invest New Drugs Date: 2010-09-21 Impact factor: 3.850

5. The synthesis of a c(RGDyK) targeted SN38 prodrug with an indolequinone structure for bioreductive drug release.

Authors: Baohua Huang; Ankur Desai; Shengzhuang Tang; Thommey P Thomas; James R Baker
Journal: Org Lett Date: 2010-04-02 Impact factor: 6.005

6. Microscopic Modes and Free Energies for Topoisomerase I-DNA Covalent Complex Binding with Non-campothecin Inhibitors by Molecular Docking and Dynamics Simulations.

Authors: Ning-Ning Wei; Adel Hamza; Ce Hao; Zhilong Xiu; Chang-Guo Zhan
Journal: Theor Chem Acc Date: 2013-08 Impact factor: 1.702

The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996.

1. In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood.

2. A self-contained enzyme activating prodrug cytotherapy for preclinical melanoma.

3. A cell-delivered and cell-activated SN38-dextran prodrug increases survival in a murine disseminated pancreatic cancer model.

4. Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine.

5. The synthesis of a c(RGDyK) targeted SN38 prodrug with an indolequinone structure for bioreductive drug release.

6. Microscopic Modes and Free Energies for Topoisomerase I-DNA Covalent Complex Binding with Non-campothecin Inhibitors by Molecular Docking and Dynamics Simulations.

7. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.

Review 8. PharmGKB summary: very important pharmacogene information for UGT1A1.

9. A risk-benefit assessment of irinotecan in solid tumours.

Review 10. Cancer therapies utilizing the camptothecins: a review of the in vivo literature.